Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on CKD-381 PK/PD in Healthy Volunteers
NCT04830930Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-381 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to the last measurable concentration and 1 more. Started Apr 2021; status: completed.
02
Drugs
CKD-381
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04830930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830930.